Ruxolitinib Topical
Jump to navigation
Jump to search
Indications
- topical treatment of
- atopic dermatitis in nonimmunocompromised adults
- non-segmental vitiligo
Contraindications
- not for ophthalmic, oral, or intravaginal use
Dosage
- atopic dermatitis
- apply thin layer of cream to affected areas BID of up to 20% body surface area
- re-evaluate if no improvment within 8 weeks
- vitiligo
- apply thin layer of cream to affected areas BID of up to 20% body surface area
- re-evaluate if no improvment within 24 weeks
- topical cream 1.5% (15 mg/g)
- do not exceed 60 g/week or one 100-gram tube/2 weeks
Storage
- store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F)
Pharmacokinetics
- peak plasma concentration of 450 nM in adults, 110 nM in adolescents
- 97% protein bound
- metabolized by CYP3A4 & to a lesser extent CYP2C9
- 1/2life of 116 hours
- 74% excreted in the urine, 22% in feces, < 1% excreted unchanged Adverse Effects
1-10%
- Nasopharyngitis (3%)
- Bronchitis (1%)
- Ear infection (1%)
- Eosinophil count increased (1%)
- Urticaria (1%)
- Diarrhea (1%)
- Folliculitis (1%)
- Tonsillitis (1%)
- Rhinorrhea (1%)
< 1%
- Neutropenia
- Allergic conjunctivitis
- Pyrexia
- Seasonal allergy
- Herpes zoster
- Otitis externa
- Staphylococcal infection
- Acneiform dermatitis
- Black Box Warnings
- Serious infections
- Mortality
- Malignancies
- Major adverse cardiovascular events (MACE)
- Thrombosis
Drug interactions
- many (see[1])
Mechanism of action
- JAK inhihitor
More general terms
References
- ↑ 1.0 1.1 Medscape: ruxolitinib topical (Rx) https://reference.medscape.com/drug/opzelura-ruxolitinib-topical-4000177